Начало・Списък с акции・CRISPR Therapeutics AG

CRISPR Therapeutics AG

Отворен

СекторЗдравеопазване

52.85 7.09

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

48.94

Максимум

52.47

Ключови измерители
By Trading Economics
Приходи	7.7M -123M
Продажби	594K 1.5M
EPS	-1.28
Марж на печалбата	-8,431.481
Служители	393
EBITDA	31M -118M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+50.21% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-315M 4.6B
Предишно отваряне	45.76
Предишно затваряне	52.85

Настроения в новините

By Acuity

24%

76%

67 / 340 Класиране в Healthcare

CRISPR Therapeutics AG Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.08.2026 г., 23:02 ч. UTC

Social Media

News

CRISPR Therapeutics reported second-quarter revenue of $10.18 million, exceeding expectations. Shares are trading higher in after-market hours following the earnings report.

31.07.2026 г., 23:06 ч. UTC

Shares of CRISPR Therapeutics AG are trading higher in after-market hours. The stock remains near the lower end of its one-month trading range.

30.07.2026 г., 23:02 ч. UTC

News

CRISPR Therapeutics shares are lower in after-market hours amid broader market weakness, despite analysts projecting revenue growth and a price target of $83.53.

29.07.2026 г., 22:01 ч. UTC

CRISPR Therapeutics AG shares are lower in after-market trading amid broader market declines driven by geopolitical tensions and caution ahead of the Fed's interest rate decision.

28.07.2026 г., 23:01 ч. UTC

Correlated Moves

CRISPR Therapeutics AG shares are lower in after-market trading, reflecting broader market trends and a decline in the Russell 2000 Index.

27.07.2026 г., 19:07 ч. UTC

CRISPR Therapeutics AG shares are higher today, gaining since Friday's close. The stock peaked earlier in the session before pulling back.

23.07.2026 г., 10:36 ч. UTC

CRISPR Therapeutics AG shares are roughly flat in pre-market hours, with no specific company news identified. The stock remains near the lower end of its trading range.

22.07.2026 г., 23:06 ч. UTC

CRISPR Therapeutics AG shares are trading higher in after-market hours, though they remain below their 20-day moving average and near the lower end of their one-month range.

21.07.2026 г., 19:26 ч. UTC

News

Correlated Moves

CRISPR Therapeutics AG shares are higher today, buoyed by a strong gene-editing pipeline and positive analyst sentiment regarding its lead asset, CASGEVY.

20.07.2026 г., 23:22 ч. UTC

CRISPR Therapeutics AG is trading higher in after-market hours, despite broader market declines linked to rising treasury yields. No specific news was identified.

Сравнение с други в отрасъла

Ценова промяна

CRISPR Therapeutics AG Прогноза

Ценова цел

By TipRanks

50.21% нагоре

12-месечна прогноза

Среден 74.46 USD 50.21%

Висок 110 USD

Нисък 45 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за CRISPR Therapeutics AG през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на CRISPR Therapeutics AG през последните 3 месеца.

Настроение

By Acuity

67 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.